Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LONGTERMS fingolimod long-term safety study in relapsing multiple sclerosis
NL-OMON47187Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fingolimod in multiple sclerosis (MS), sponsored by Novartis. Primary endpoint: Safety and tolerability. Started Dec 2010; status: active, not recruiting.
02
Drugs
fingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON47187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47187.